https://beonehcp.com/ch-en/medical-affairs/celestial-tncll-an-ongoing-open-label-multiregional-phase-3-study-of-sonrotoclax-bgb-11417-zanubrutinib-vs-venetoclax-obinutuzumab-for-treatment-naive-cll/ 2026-07-03T12:54:45+00:00 https://beonehcp.com/ch-en/medical-affairs/bgb-16673-a-bruton-tyrosine-kinase-degrader-in-patients-with-relapsed-refractory-waldenstrom-macroglobulinemia-a-phase-1-cadance-101-study-update/ 2026-07-03T12:54:51+00:00 https://beonehcp.com/ch-en/medical-affairs/tacabrutideg-bgb-16673-a-bruton-tyrosine-kinase-degrader-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-a-phase-1-cadance-101-study-update/ 2026-07-03T12:54:55+00:00 https://beonehcp.com/ch-en/medical-affairs/sonrotoclax-bgb-11417-plus-zanubrutinib-vs-venetoclax-plus-acalabrutinib-in-treatment-naive-chronic-lymphocytic-leukemia-a-phase-3-randomized-trial-design-celestial-tncll-2/ 2026-07-03T12:54:58+00:00 https://beonehcp.com/ch-en/medical-affairs/combination-treatment-with-novel-b-cell-lymphoma-2-inhibitor-sonrotoclax-bgb-11417-and-zanubrutinib-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-results-from-a-phase-1-1b-study/ 2026-07-03T12:55:03+00:00 https://beonehcp.com/ch-en/medical-affairs/first-line-treatment-of-cll-sll-with-the-all-oral-combination-of-sonrotoclax-and-zanubrutinib-achieves-undetectable-minimal-residual-disease-rates-of-90-including-in-patients-with-del17p-tp53/ 2026-07-03T12:55:07+00:00